At The Cutting Edge of Developments in the Management of Hyperkalemia

Program Goals

Recent Clinical Trial Data on Potassium Binders: Patiromer

OPAL-HK Phase 3 Pivotal Study Design

OPAL-HK Initial Treatment Phase

OPAL-HK: Phase 3 Study Part B Effect on Concomitant RAAS Inhibitor Therapy

Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer in Hyperkalemic Patients With CKD*

Use of Antihypertensive Medications and Hyperkalemia

Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Healthcare System: Study Design

PATHWAY-2 Optimal Treatment for Resistant Hypertension

Need for Potassium Binding Agents

Recent Clinical Trial Data on Potassium Binders: ZS-9

ZS-9*: Potassium Levels During the Acute and Maintenance Phase

Long-term Safety and Efficacy of ZS-9 in the Treatment of Hyperkalemia

Interim Safety Results of 52-week Trial of ZS-9 in Patients With Hyperkalemia

Implications of New and Emerging Potassium Binders in Clinical Practice

Hyperkalemia in Patients on Dialysis

Frequency of Hyperkalemia Events in Dialysis Patients

Serum Potassium and Mortality in Hemodialysis Patients

Developments in the Management of Hyperkalemia

Abbreviations

Abbreviations (cont)